Slides
Page 1
& Not for promotional use
Page 2
Q3 2026 Earnings Call Eli Lilly and Company
Page 3
2026 Q3 Earnings 3 Agenda Introduction and Key Events David Ricks, Chair and Chief Executive Officer Q3 2026 Financial Results Lucas Montarce, Chief Financial Officer R&D Update Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer Question & Answer Session
Page 4
2026 Q3 Earnings Not for promotional use 4 Safe Harbor Provision and Other Information This presentation contains forward - looking statements that are based on management's current expectations, but actual results ma y differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; tra de and economic conditions; the implementation of our voluntary agreement with the U.S. government related to drug pricing and access; and changes in law s a nd regulations, including healthcare reform. For additional information about the factors that affect the company's business, please see the company's latest Form 10 - K and subsequent Forms 10 - Q and 8 - K filed with the Securities and Exchange Commission. Certain financial information in this prese ntation is presented on a non - GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's no n - GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to pr omo te the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation hav e n ot been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated. Numbers in this presentation may not add due to rounding. Market positions represent estimates for performance based on indicated data sources. These figures do not reflect Lilly's sh are of any relevant antitrust market and do not include the full set of therapeutic or other alternatives reasonably available to patien ts and prescribers. The company undertakes no duty to update forward - looking statements except as required by applicable law.
Page 5
2026 Q3 Earnings Not for promotional use 5 Q3 2026 Progress on Strategic Deliverables • Started construction on a $6.5B manufacturing site in Houston, TX and a $5B site in Richmond, VA • Completed acquisitions of AtaiBeckley and Merida Biosciences • Key Product revenue grew 100% across Oncology, Immunology and Neuroscience • FDA approval of Inluriyo in combination with Verzenio in advanced breast cancer • FDA approval of Jaypirca in 1L CLL/SLL • Positive Phase 3 data from Ebglyss in moderate - to - severe hand and foot atopic dermatitis • Incretin revenue grew 54% driven by market growth and increased global share • FDA approval of Onswik for adults with type 2 diabetes • FDA approval of Mounjaro to reduce CV risk in adults with type 2 diabetes • Positive Phase 3 data from retatrutide vs. Ozempic 2.0 mg in type 2 diabetes $24.4B↑ 39% $7.48↑ 7% +62% Q3 WORLDWIDE REVENUE KEY PRODUCT REVENUE GROWTH NON-GAAP EPS Growth rates reflect change vs. Q3 2025 The Company currently defines Key Products as Ebglyss , Foundayo , Inluriyo , Jaypirca , Kisunla , Mounjaro, Omvoh , and Zepbound Incretins include Foundayo , Mounjaro, Zepbound, and Trulicity Invest to Drive Future Growth Expand Presence in Other Therapeutic Areas Broaden Impact on Cardiometabolic Health
Page 6
2026 Q3 Earnings Not for promotional use 6 Medicare GLP - 1 Bridge Update 7 out of 10 New - to - Bridge patients are choosing Lilly obesity medicines 500K+ Patients accessing Lilly obesity medicines via Bridge 80% Of Lilly Bridge patients are new incretin starts Sources: company data and IQVIA data for Q3 2026 222 396 527 - 100 200 300 400 500 600 Jul-26 Aug-26 Sep-26 Monthly Lilly Medicare GLP - 1 Bridge Scripts (thousands)
Page 7
2026 Q3 Earnings GAAP Reported Adjustments Non - GAAP Adjusted YoY Non - GAAP Adjusted Change Total revenue $24,397 $ - $24,397 39% Gross margin 83.9% 0.5pp 84.4% +0.8pp Total operating expense $11,856 $(303) $11,553 68% Operating income $8,608 $431 $9,039 15% Other income (expense) $(202) $(47) $(249) 38% Effective tax rate 23.3% +0.7pp 24.0% +6.3pp Net income $6,451 $228 $6,679 6% EPS $7.22 $0.26 $7.48 7% Acquired IPR&D Charge per share 1 $4.57 $ - $4.57 NM Performance Margin 2 52.4% 54.2% +5.9pp 1 Acquired IPR&D (in - process research and development) charge of $4.2 billion (pre - tax). Not for promotional use 7 2 The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and ass et impairment, restructuring and other special charges divided by revenue Note: The Non - GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of i ntangible assets can be found in the reconciliation tables on slide 24 ; NM = not meaningful Dollars in millions; except per share data Q3 2026 Key Income Statement Measures (unaudited)
Page 8
2026 Q3 Earnings Amount Price FX Rate Volume Total CER U.S. $15,136 (7)% - 41% 34% 34% Europe $4,459 3% (1)% 26% 28% 29% Japan $648 (10)% (10)% 36% 16% 26% China 1 $947 NM 7% NM 69% 62% Rest of world $3,206 (2)% 3% 90% 90% 87% Total Revenue $24,397 (15)% 0% 53% 39% 39% Dollars in millions. Numbers may not add due to rounding. CER= price change + volume change; NM = not meaningful 1 China price and volume driven by inclusion of Mounjaro on National Reimbursement Drug List for Type 2 Diabetes, with lower pr ice and higher volume vs. Q3 2025 and YTD 2025 Dollars in m illions Not for promotional use 8 Price/Rate/Volume Effect on Revenue Q3 2026 Amount Price FX Rate Volume Total CER U.S. $41,668 (5)% - 42% 36% 36% Europe $12,219 4% 5% 35% 44% 39% Japan $1,847 (6)% (7)% 38% 25% 32% China 1 $2,582 NM 6% NM 75% 69% Rest of world $8,854 (3)% 6% 126% 129% 123% Total Revenue $67,170 (14)% 1% 59% 46% 45% YTD 2026
Page 9
2026 Q3 Earnings $0 $2,000 $4,000 $6,000 $8,000 $10,000 $12,000 $14,000 $16,000 $18,000 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2023 2024 2025 2026 Millions Not for promotional use 9 Cardiometabolic Health Mounjaro extended its U.S. TRx share lead to 56% and continued growth in International Incretin Analogs share Zepbound maintained U.S. TRx share leadership, exiting Q3 at 58% Foundayo continued to grow U.S. NBRx share and launched in several additional geographies Immunology Ebglyss became the fastest growing medicine for moderate - to - severe atopic dermatitis in the U.S. Oncology Jaypirca was approved by the FDA for certain patients in first - line CLL and SLL Inluriyo exited Q3 with more than 60% NBRx share in the U.S. Neuroscience Kisunla maintained market leadership in the U.S. Q3 2026 Update on Key Products $17.1B Key Product revenue grew 62 % year over year The Company currently defines Key Products as Ebglyss, Foundayo (added Q2 2026), Inluriyo (added Q4 2025), Jaypirca, Kisunla, Mo unjaro, Omvoh, and Zepbound. +100% Key Product revenue growth in Immunology, Oncology & Neuroscience
Page 10
2026 Q3 Earnings 0 300 600 900 1,200 1,500 1,800 2,100 2,400 2,700 3,000 Source: IQVIA weekly NPA total prescriptions, weekly data 9/25/2026 Rolling 4 week SOM. Incretin analogs market includes injectable GLP - 1s, oral GLP - 1s and GLP - 1/GIP dual agonists Not for promotional use 10 Total Prescriptions 4 Week Rolling Average (thousands) U.S. Incretin Analogs Market +32% Q3 2026 U.S. market growth 63.0% Lilly share of market Lilly SOM 63.0 % Total Prescriptions Novo SOM 36.6%
Page 11
2026 Q3 Earnings International Incretin Analogs Market $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 $3.0 Gross Revenue 3 Month Rolling Average (billions) Not for promotional use 11 +53% Q3 2026 market growth 58.4% Lilly share of market Growth rate: July/August 2026 vs. July/August 2025; Q3 2026 reflects two months of data Data source: IQVIA GMI Agent AI, MIDAS Monthly accessed 10/26/2026 Sales in US dollars at the exchange rate in effect at the time of sale based on wholesaler purchase price and manufacturer’s selling price Market basket: branded incretins including Bydureon /Byetta, Foundayo, Lyxumia , Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Wegovy, Victoza, Zepbound Geography: Worldwide excluding USA and Puerto Rico Lilly SOM 58.4% Total Revenue Novo SOM 41.6%
Page 12
2026 Q3 Earnings 0% 5% 10% 15% 20% 25% 30% 35% 40% 0 5 10 15 20 25 30 35 40 45 50 Apr-26 May-26 Jun-26 Jul-26 Aug-26 Sep-26 New to Brand Share of Market 4 Week Rolling Average New to Brand Prescriptions 4 Week Rolling Average (thousands) Broad c ommercial formulary and Medicare access for obesity Not for promotional use Foundayo Launch Progress Share of new patient starts exited Q3 at ~40% Now launched in: UAE, Mexico, Saudi Arabia and UK Under regulatory review in 40+ countries 12 Growing consumer brand interest and HCP prescriber base NBRx SOM NBRx
Page 13
2026 Q3 Earnings R&D 2 Capital Investments Business Development 1 Dividend Share Repurchase 1 Includes development milestones, closed acquisitions and cash outflows associated with equity investments 2 After tax Not for promotional use 13 YTD 2026 Capital Allocation $ in b illions GROWTH RETURN $8.4 $9.5 $19.0 $4.3 $4.6
Page 14
2026 Q3 Earnings Not for promotional use 14 Prior Updated Comments Revenue 1 $85.0 – $87.0 billion $91.0 – $92.0 billion Strong underlying business performance Performance Margin 2 49.0% – 50.5% 52.0% – 52.5 % Increased midpoint by 2.50 ppts to reflect updated revenue expectations Tax Rate Approximately 18 - 19% Approximately 19 – 20% Increased due to acquired IPR&D charges Earnings Per Share 3 $35.50 – $36.50 $35.00 – $36.00 Increased $4.07 at midpoint to reflect updated revenue expectations before updating guidance for $4.57 impact of Q3 2026 acquired IPR&D charges 2026 Guidance (Non - GAAP) 1 GAAP measure 2 The Company define s Non - GAAP Performance Margin as gross margin less research and development and marketing, selling, and administrative expenses d ivided by revenue. 3 2026 assumes shares outstanding of approximately 894 million Note: See slide 25 for additional Non - GAAP information. FX assumptions of 1.13 (Euro), 157 (Yen) and 6.7 (Yuan)
Page 15
2026 Q3 Earnings TRANSCEND - T2D - 2 Topline Results Not for promotional use 15 Participants with T2D on metformin with or without an SGLT2 Key Highlights: Retatrutide demonstrated greater HbA1c reduction and weight loss vs. Ozempic’s highest approved dose Retatrutide delivered more than double the weight loss vs. Ozempic Treatment discontinuation rates due to AEs were 5 - 8% on retatrutide vs. 3% on Ozempic - 9.6 kg - 20.0 kg - 21.4 kg - 1.8% - 2.2% - 2.2% HbA1c Change Body Weight Change Baseline HbA1c = 8.3% Baseline Weight = 102.4 kg HbA1c and Body Weight Change at 80 Weeks 1 Ozempic 2.0 mg Retatrutide 9 mg Retatrutide 12 mg - 9.4% - 20.9% - 19.5% 1 Efficacy Estimand . The primary endpoint was 12mg change in A1c vs semaglutide. 9mg change in A1c and change in body weight for both dosages w ere key secondary endpoints.
Page 16
2026 Q3 Earnings Not for promotional use 16 EloraTZP Phase 2 Weight Loss & A1C Participants with Obesity or Overweight and T2D 1 Select primary and secondary endpoints. Data in line plot are the mean observed data while all other data are model based est ima tes using efficacy estimand data set. EE = efficacy estimand ; Elora=eloralintide; TZP=tirzepatide; T2D=type 2 diabetes Percent Change from Baseline HbA1c 1 (8.1%) Percent Change from Baseline Body Weight 1 (105.4 kg) Change From Baseline in Body Weight (%) Weeks Weeks Change From Baseline in HbA1c (%) EloraTZP was associated with greater weight and A1C reduction vs. either therapy alone Placebo Elora 9 mg TZP 15 mg Elora 9 mg + TZP 15 mg EE EE -30 -25 -20 -15 -10 -5 0 0 4 8 12 16 20 24 36 48 - 3.0% - 14.8% - 11.1% - 23.3% -4 -3 -2 -1 0 0 12 24 36 48 - 0.29% - 2.41% - 1.33% - 2.91%
Page 17
2026 Q3 Earnings Not for promotional use 17 EloraTZP Safety & Tolerability 9 mg 16% 18% 13% 11% 8% - - 9 mg +15 mg 49% 30% 14% 24% 24% 24% 27% 15 mg 26% 23% 20% 14% 17% 11% 3% Placebo 11% 19% 8% 8% - 6% 17% Treatment Emergent Adverse Events (%) 1 Nausea Diarrhea Constipation Fatigue Decreased appetite Vomiting Discontinuation due to Adverse Events Eloralintide EloraTZP TZP Eloralintide showed favorable GI tolerability The types of AEs observed with EloraTZP are consistent with those in other incretin therapies 1 Select tolerability data. Elora=eloralintide; TZP=tirzepatide
Page 18
2026 Q3 Earnings 1 Time to first event analysis using Cox proportional hazard model 2 Pre - planned analysis not multiplicity controlled for family - wise type - 1 error Not for promotional use 18 Foundayo ACHIEVE - 4 Results Participants with T2D and Obesity or Overweight Fewer Events of All Cause Death 2 with Foundayo Foundayo Non - Inferior to Insulin Glargine in MACE - 4 1 HR, 0.43 (95% CI, 0.25 - 0.75) HR, 0.84 (95% CI, 0.59 – 1.20) Insulin Glargine (67 Events) Foundayo MTD (57 Events) Insulin Glargine (43 Events) Foundayo MTD (19 Events) Foundayo demonstrated cardiovascular safety and sustained A1C reduction and weight loss vs. insulin glargine 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% 7.0% 8.0% 9.0% 10.0% 0 12 24 36 48 60 72 84 96 108 Time From Randomization (Weeks) Cumulative Probability Cumulative Probability 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0% 4.5% 5.0% 0 12 24 36 48 60 72 84 96 108 Time From Randomization (Weeks)
Page 19
2026 Q3 Earnings XCL1/2 Ab Alopecia Areata BRENIPATIDE COPD DONANEMAB Dementia with Lewy bodies PIRTOBRUTINIB ITP TIRZEPATIDE Higher Doses ZOTEMTEGRAST + MIRIKIZUMAB UC ZOTEMTEGRAST Crohn’s Disease BRENIPATIDE Schizophrenia BRENIPATIDE Tobacco Use Disorder ELTREKIBART Ulcerative Colitis BRENIPATIDE IBS - C BRENIPATIDE IBS - D BRENIPATIDE Opioid Use Disorder R - MDMA Psychiatric Disorders BRENIPATIDE Asthma BRENIPATIDE Bipolar Disorder ZOTEMTEGRAST Ulcerative Colitis BUCCAL FILM DMT MDD INTRANASAL 5 - MeO - DMT TRD SOLBINSIRAN Severe Hypertriglyceridemia TURIGROBART Pain XCL1/2 Ab Vitiligo NISOTIROSTIDE Diabetes PARUNOFLAST (VTX3232) Inflammatory Disorders SIMEPDEKINRA Psoriasis MACUPATIDE + ELORALINTIDE Obesity NAPERIGLIPRON Obesity NAV1.8 INH (SM) Pain GBA1 GENE THERAPY Parkinson’s Disease GIPR AGONIST LA CINV GS INSULIN RECEPTOR AGONIST Diabetes CLEMINOREXTON Central Hypersomnias ELTREKIBART Hidradenitis Suppurativa FXR AGONIST + MIRIKIZUMAB CD AT2R ANTAGONIST Pain BIMAGRUMAB Obesity CLAZAKIZUMAB Inflammatory Disorders ABDENOFLAST (VTX2735) Recurrent Pericarditis AIPL1 GENE THERAPY AIPL1 - IRD AMEZOSVATEIN Shingles Not for promotional use 19 TIRZEPATIDE Type 1 Diabetes SELPERCATINIB Adjuvant RET+ NSCLC SOFETABART MIPITECAN PSOC TIRZEPATIDE MASLD TIRZEPATIDE Morbidity and Mortality in Obesity RETATRUTIDE Chronic Low Back Pain RETATRUTIDE CV / Renal Outcomes RETATRUTIDE Diabetes RETATRUTIDE MASLD ORFORGLIPRON Osteoarthritis Pain ORFORGLIPRON Peripheral Artery Disease ORFORGLIPRON Stress Urinary Incontinence PIRTOBRUTINIB R/R MCL Monotherapy OLOMORASIB Adj KRAS G12C+ NSCLC (unresected) ORFORGLIPRON Cardiovascular Outcomes ORFORGLIPRON Hypertension ORFORGLIPRON Obstructive Sleep Apnea MIRIKIZUMAB + TIRZEPATIDE CD MIRIKIZUMAB + TIRZEPATIDE UC OLOMORASIB 1L KRAS G12C+ NSCLC (PD - L1 high) OLOMORASIB Adj KRAS G12C+ NSCLC (resected) ELORALINTIDE Osteoarthritis Pain IMLUNESTRANT Adjuvant Breast Cancer LEBRIKIZUMAB AR (perennial allergens) LEBRIKIZUMAB CRSwNP BRENIPATIDE Major Depressive Disorder DONANEMAB Cognitively Unimpaired AD ELORALINTIDE INCRETIN ADD - ON Obesity ELORALINTIDE Obstructive Sleep Apnea SOFETABART MIPITECAN PROC OTOF GENE THERAPY Hearing Loss TERSOLISIB PIK3CA+ Advanced Breast Cancer BARICITINIB Type 1 Diabetes MUVALAPLIN ASCVD OLOMORASIB 1L KRAS G12C+ NSCLC (All PD - L1) REMTERNETUG Cognitively Unimpaired / MCI due to AD RETATRUTIDE Obesity, OA, OSA BRENIPATIDE Alcohol Use Disorder ELORALINTIDE Obesity IXO - VEC wet Age - Related Macular Degeneration LEPODISIRAN ASCVD PIRTOBRUTINIB R/R CLL Combination ORFORGLIPRON Diabetes Lilly Select Pipeline October 27 , 2026 PHASE 2 PHASE 3 REG REVIEW NME NILEX / Other UPDATES SINCE August 3, 2026 REMOVAL ADDITION OR MILESTONE ACHIEVED MEVIDALEN Symptomatic AD TIRZEPATIDE Cardiovascular Outcomes INSULIN EFSITORA ALFA Diabetes APPROVED
Page 20
2026 Q3 Earnings Not for promotional use 20 Potential Key Events 2026 New since last update Eloralintide for obesity or overweight Eloralintide incretin add - on for obesity or overweight Eloralintide for OA knee pain and obesity or overweight Eloralintide for OSA and obesity or overweight Orforglipron for peripheral artery disease Vepugratinib for 1L metastatic urothelial cancer Tersolisib for advanced breast cancer Sofetabart Mipitecan for platinum - resistant ovarian cancer Sofetabart Mipitecan for platinum - sensitive ovarian cancer Brenipatide for major depressive disorder Baricitinib for type 1 diabetes Phase 3 Initiations Ixekizumab and tirzepatide for psoriatic arthritis and obesity or overweight Ixekizumab and tirzepatide for psoriasis and obesity or overweight Orforglipron for type 2 diabetes [ACHIEVE - 4] Orforglipron for obstructive sleep apnea and obesity or overweight Retatrutide for obesity or overweight [TRIUMPH 1 /2 /3 ] Retatrutide for type 2 diabetes [TRANSCEND - T2D 1 /2 /3] Lebrikizumab for pediatric atopic dermatitis Pirtobrutinib for R/R CLL combination [BRUIN CLL - 322] Phase 3 Data Disclosures Orforglipron for type 2 diabetes [US / EU /J ] Orforglipron for obstructive sleep apnea and obesity or overweight Pirtobrutinib for R/R CLL combination Selpercatinib for adjuvant RET fusion - positive non - small cell lung cancer Lebrikizumab for pediatric atopic dermatitis Regulatory Submissions Regulatory Actions Zepbound KwikPen [US] Tirzepatide for cardiovascular outcomes Orforglipron for overweight or obesity [US] Orforglipron for type 2 diabetes Insulin efsitora alfa for type 2 diabetes Pirtobrutinib for 1L CLL Imlunestrant + abemaciclib for ER+, HER2 - mBC Lebrikizumab maintenance dosing once every 8 weeks
Page 21
2026 Q3 Earnings Not for promotional use 21 Q3 2026 Summary Invest to Drive Future Growth Expand Presence in Other Therapeutic Areas Broaden Impact on Cardiometabolic Health ↑ 39% $7.48 Revenue growth Non - GAAP EPS $91.0B - $92.0B $35.00 - $36.00 Increased full year revenue guidance N on - GAAP EPS guidance 1 Acquisition announced $11.5B New Manufacturing sites 1 New medicine approved 2 New Phase 3 programs 3 New indications
Page 22
2026 Q3 Earnings Not for promotional use 22 Supplemental Slides 2026 Q3 Earnings
Page 23
2026 Q3 Earnings Not for promotional use 23 2026 Income Statement – Reported * Includes research and development expense; marketing, selling and administrative; acquired in - process research and development charges; and asset impairment, restructuring and other special charges (as applicable) Q3 2026 Change Total revenue $24,397 39% Gross margin 83.9% +1.0pp Total operating expense* $11,856 64% Operating income $8,608 17% Operating margin 35.3% - 6.5pp Other income (expense) $(202) 53% Effective tax rate 23.3% +0.5pp Net income $6,451 16% EPS $7.22 16% Dollars in millions; except per share data
Page 24
2026 Q3 Earnings Not for promotional use 24 Q3 2026 Q3 2025 % Change Earnings per share (reported) $7.22 $6.21 16% Asset impairment, restructuring and other special charges 0.18 0.36 (50)% Amortization of intangible assets 0.11 0.11 0% Net losses (gains) on investments in equity securities (0.04) (0.04) 0% US tax law changes -- 0.39 NM Earnings per share (Non - GAAP) $7.48 $7.02 7% Acquired IPR&D $4.57 $0.71 NM Numbers may not add due to rounding; see slide 25 for more details on these adjustments; NM = not meaningful EPS Reconciliation
Page 25
2026 Q3 Earnings Not for promotional use 25 Q3 Non - GAAP Adjustments Q3 2026 non - GAAP information has been adjusted to exclude: • Asset impairment, restructuring and other special charges, primarily related to the partial impairment of an intangible asset associated with a molecule in development, totaling $303 million (pre - tax), or $0.18 per share (after - tax) • Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $128 million (pre - tax), or $0.11 per share (after - tax) • Net gains on investments in equity securities totaling $47 million (pre - tax), or ($0.04) per share (after - tax) Q3 2025 non - GAAP information has been adjusted to exclude: • Asset impairment, restructuring and other special charges, primarily related to a litigation charge, as well as acquisition and integration costs, totaling $365 million (pre - tax), or $0.36 per share (after - tax) • Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $119 million (pre - tax), or $0.11 per share (after - tax) • Net gains on investments in equity securities totaling $48 million (pre - tax), or ($0.04) per share (after - tax) • Income taxes related to U.S. tax law changes effective July 4, 2025, including the remeasurement of deferred taxes, totaling $350 million, or $0.39 per share
Page 26
2026 Q3 Earnings 0 200 400 600 800 1,000 1,200 1,400 1,600 0% 10% 20% 30% 40% 50% 60% Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 13 Wk RA TRX Market Size 13 wk RA TRx SOM Not for promotional use 26 Q3 2026 Mounjaro Sales Increased $4.2B U.S. TRX SOM and Market Volume Source: IQVIA NPA TRx 3MMA, weekly data September 25, 2026; RA = rolling average TRx data is representative of the Incretin Analogs - type 2 diabetes market Mounjaro U.S. sales were $5.0 billion International sales were $5.7 billion Market $ in billions $3.8 $5.2 $6.5 $7.4 $8.7 $9.9 $10.7 Q1 Q2 Q3 Q4 2025 2026
Page 27
2026 Q3 Earnings 0 200 400 600 800 1,000 1,200 1,400 1,600 0% 10% 20% 30% 40% 50% 60% 70% Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 13 Wk RA TRX Market Size 13 wk RA TRx SOM Not for promotional use 27 Q3 2026 Zepbound Sales Increased $1.8B $2.3 $3.4 $3.6 $4.3 $4.2 $4.9 $5.4 Q1 Q2 Q3 Q4 2025 2026 Source: IQVIA NPA TRx 3MMA, weekly data September 25 , 2026; RA = rolling average TRx data is representative of the branded incretin analogs – OMM market Zepbound Market 1 Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States . International sales were $86 million in Q3 2026 U.S. sales were $5.3 billion 1 $ in billions U.S. TRX SOM and Market Volume
Page 28
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT031559971 Breast Cancer Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) 3 5637 Invasive Disease-Free Survival Mar 2020 May 2029 NCT05169567 Breast Cancer Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH) 3 368 Progression-Free Survival (PFS) Feb 2024 Dec 2027 Not for promotional use 28 Source: clinicaltrials.gov, October 20, 2026 Select Trials – Abemaciclib 1 Also lists NSABP Foundation Inc * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 29
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07222332 Type 1 Diabetes A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) 3 300 Change from Baseline in C-peptide Area Under the Curve (AUC) Jul 2028 Jul 2028 NCT07222137 Type 1 Diabetes A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) 3 150 Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes Jul 2031 Jul 2031 Not for promotional use 29 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Baricitinib
Page 30
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07412756 Major Depressive Disorder A Study of Brenipatide in Adult Participants With Major Depressive Disorder (RENEW-MDD-1) 3 1000 Time to Relapse as Measured by Number of Days from Randomization to Date Participant Meets Any Relapse Criterion of MDD Feb 2028 Feb 2028 NCT07775300 Major Depressive Disorder A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder (RENEW- MDD-2) 3 1000 Time to Relapse Defined as the Number of Days from Randomization to Date on Which the Participant Meets Any Relapse Criterion of Major Depressive Disorder (MDD) Dec 2028 Feb 2029 NCT07219966 Alcohol Use Disorder A Study of Brenipatide in Participants With Moderate- to-Severe Alcohol Use Disorder (RENEW-ALC-1) 3 1100 Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB) Apr 2028 Apr 2028 NCT07219953 Alcohol Use Disorder A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2) 3 1100 Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB) Apr 2028 Apr 2028 NCT07420283 Opioid Use Disorder A Study of Brenipatide in Participants With Opioid Use Disorder (RENEW-Op-1) 2 465 Percentage of weeks abstinence from opioid use defined by both negative urine drug screen (UDS) and no self-report of opioid use based on Timeline Followback (TLFB); achievement of ≥80% weeks of abstinence from opioid use defined by both negative UDS and no self-report of opioid use based on TLFB Mar 2028 Mar 2028 NCT07286175 Bipolar Disorder A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) 2 400 Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion Nov 2027 Nov 2027 NCT07223840 Tobacco Use Disorder A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1) 2 222 Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips Feb 2027 Feb 2027 Not for promotional use 30 Source: clinicaltrials.gov, October 20, 2026 Select Trials – Brenipatide * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 31
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07410507 Schizophrenia A Study of Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1) 2 450 Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²) Nov 2027 Nov 2027 NCT07219173 Asthma A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate-to-Severe Asthma (RENEW-Asthma) 2 531 Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment Apr 2028 Jun 2028 NCT07545759 Irritable Bowel Syndrome / Diarrhea A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (RENEW-IBS- D) 2 531 Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days Sep 2027 Nov 2027 NCT07545772 Irritable Bowel Syndrome / Constipation A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (RENEW- IBS-C) 2 342 Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks Jul 2027 Sep 2027 NCT07759245 Chronic Obstructive Pulmonary Disease A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) (RENEW-COPD) 2 606 Change from Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1) May 2028 Nov 2028 Not for promotional use 31 Source: clinicaltrials.gov, October 20, 2026 Select Trials – Brenipatide (cont.) * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 32
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04437511 Alzheimer's Disease A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) 3 1736 Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population) Apr 2023 Nov 2028 NCT05026866 Alzheimer's Disease A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER- ALZ 3) 3 2996 Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) Nov 2027 Nov 2027 NCT05508789 Alzheimer's Disease A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) 3 1500 Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) May 2028 Jul 2028 NCT05738486 Alzheimer's Disease A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) 3 1175 Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E) May 2024 May 2027 NCT07571161 Alzheimer’s Disease Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease 3 140 Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS) Apr 2030 Apr 2030 NCT07602582 Alzheimer's Disease / Dementia / Plaque, Amyloid A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3- EXT) 3 550 Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB) Sep 2029 Sep 2029 NCT07589595 Cognitive Dysfunction / Lewy Body Disease / Synucleinopathies / Amyloid A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology (TRAILBLAZER-ALZ 7) 2 350 Change from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB) Aug 2028 Aug 2028 Not for promotional use 32 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Donanemab
Page 33
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07321886 Obesity / Overweight A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (ENLIGHTEN-1) 3 1980 Percent Change from Baseline in Body Weight Mar 2028 Jul 2030 NCT07282600 Obesity / Overweight A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2) 3 1035 Percent Change from Baseline in Body Weight Jan 2028 Feb 2028 NCT07369011 Obstructive Sleep Apnea / Obesity A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3) 3 800 Percent Change from Baseline in Body Weight and Change from Baseline in Apnea-Hypopnea Index Mar 2028 Apr 2028 NCT07353931 Osteoarthritis / Overweight Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4) 3 900 Percent Change from Baseline in Body Weight and Change from Baseline in WOMAC Pain Subscale Score Mar 2028 May 2028 NCT07392190 Obesity / Overweight A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6) 3 900 Percent Change from Baseline in Body Weight Jun 2028 Jul 2028 Not for promotional use 33 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Eloralintide
Page 34
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04975308 Breast Neoplasms A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) 3 874 Progression-Free Survival (PFS) Jun 2024 Aug 2027 NCT05514054 Breast Neoplasms A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) 3 8000 Invasive Disease-Free Survival (iDFS) Oct 2027 Mar 2032 NCT07287098 Breast Neoplasms A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (preEMBER) 2 600 Percent Change from Baseline in Ki67 Jan 2029 Dec 2029 Not for promotional use 34 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Imlunestrant
Page 35
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06856577 Neovascular Age-Related Macular Degeneration Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (ARTEMIS) 3 311 Mean Change from Baseline in Best Corrected Visual Acuity (BCVA) Dec 2026 Nov 2030 NCT07482176 Neovascular Age-Related Macular Degeneration Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (AQUARIUS) 3 534 Mean Change from Baseline in Best Corrected Visual Acuity (BCVA) Nov 2027 Oct 2031 Not for promotional use 35 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Ixo - vec
Page 36
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05559359 Atopic Dermatitis A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1) 3 377 Percentage of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 16 and a Reduction ≥2 points from Baseline Jan 2026 Dec 2026 NCT05735483 Atopic Dermatitis A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2) 3 338 Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs) Dec 2027 Apr 2029 NCT06339008 Perennial Allergic Rhinitis A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) 3 450 Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16 Oct 2026 Oct 2028 NCT06338995 Chronic Rhinosinusitis With Nasal Polyps A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) 3 510 Mean Change From Baseline (CFBL) in Participant- Reported Nasal Congestion Score (NCS) Severity May 2027 Mar 2028 Not for promotional use 36 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Lebrikizumab
Page 37
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06292013 Atherosclerotic Cardiovascular Disease1 A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) – ACCLAIM-Lp(a) 3 17300 Time to First Occurrence of Any Component of the Major Adverse Cardiovascular Event (MACE)-4 Composite Endpoint Mar 2029 Mar 2029 NCT07613294 Atherosclerosis / Cardiovascular Diseases / Lipoprotein(a) A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk – ACCLAIM-CTA 3 252 Percent Change from Baseline in Noncalcified Plaque (NCP) Volume Dec 2029 Dec 2029 Not for promotional use 37 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Lepodisiran 1 Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at risk for ASCVD
Page 38
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT03519945 Ulcerative Colitis A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) 3 1058 Percentage of Participants in Clinical Remission Mar 2026 Dec 2027 NCT04232553 Crohn's Disease A Long-Term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2) 3 996 Percentage of Participants Achieving Endoscopic Response Nov 2024 Mar 2028 NCT05509777 Crohn's Disease A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY) 3 90 Percentage of Participants With Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52 Dec 2027 Apr 2028 NCT06937099 Crohn's Disease / Obesity Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT- CD) 3 290 Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at Least 10% Weight Reduction May 2028 May 2028 NCT06937086 Ulcerative Colitis / Obesity Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) 3 350 Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction Apr 2028 Apr 2028 NCT07186101 Ulcerative Colitis LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis (TOPAZ-UC) 2 252 Percentage of Participants Who Achieve Clinical Remission With Modified Mayo Score (mMS) May 2027 Mar 2029 NCT06598943 Ulcerative Colitis A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis 2 143 Percentage of Participants Achieving Clinical Remission Aug 2026 Jul 2027 Not for promotional use 38 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Mirikizumab
Page 39
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07157774 Atherosclerotic Cardiovascular Disease1 Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a)) 3 10450 Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint Mar 2031 Mar 2031 Not for promotional use 39 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Muvalaplin 1 Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at risk for ASCVD
Page 40
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06119581 Carcinoma, Non-Small-Cell Lung A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer (SUNRAY-01) 3 1264 Dose Optimization and Safety Lead-In Part B: Number of Participants With a TEAE Nov 2027 Jan 2031 NCT068905981 Carcinoma, Non-Small-Cell Lung Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-Mutant Non-Small Cell Lung Cancer (SUNRAY-02) 3 700 Part A: Disease-Free Survival (DFS) by Investigator Assessment May 2029 Feb 2032 Not for promotional use 40 Source: clinicaltrials.gov, October 20, 2026 Select Trials – Olomorasib 1 Also lists AstraZeneca * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 41
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05869903 Obesity / Overweight A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) 3 3127 Mean Percent Change from Baseline in Body Weight Jul 2025 Oct 2027 NCT06672939 Obesity / Overweight A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity or Overweight With Related Comorbidities 3 150 Percent Change from Baseline in Body Mass Index (BMI) Dec 2027 Jan 2031 NCT06948422 Hypertension A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) 3 974 Change from Baseline in Systolic Blood Pressure Sep 2027 Sep 2027 NCT07241390 Cardiovascular Disease / Chronic Kidney Disease A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) 3 7140 Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events Aug 2031 Aug 2031 NCT07153471 Osteoarthritis A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (ATTAIN-OA PAIN) 3 800 Change from Baseline in WOMAC Pain Subscale Score Apr 2028 May 2028 NCT07223593 Peripheral Artery Disease Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (ATTAIN-PAD) 3 1205 Percent Change from Baseline in Maximum Walking Distance Jun 2028 Jun 2028 NCT07202884 Stress Urinary Incontinence / Obesity A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) 3 1000 Change from Baseline in Incontinence Episode Frequency (IEF) Mar 2028 Mar 2028 Not for promotional use 41 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Orforglipron
Page 42
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06972459 Obesity / Overweight A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity 3 800 Percent Change from Baseline in Body Weight Aug 2027 Aug 2027 NCT06972472 Obesity / Overweight A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes 3 600 Change from Baseline in Hemoglobin A1c (HbA1c) Aug 2027 Aug 2027 NCT07668336 Diabetes Mellitus, Type 2 A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes 3 170 Change from Baseline in Hemoglobin A1c (HbA1c) Mar 2030 Mar 2030 NCT07613307 Diabetes Mellitus, Type 2 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting 3 130 Change from Baseline in Hemoglobin A1c (HbA1c) May 2027 May 2027 NCT07794579 Overweight / Prediabetes / Prehypertension A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity- Related Complications or Progression to Class 1 Obesity (ATTAIN-NOW) 3 2001 Time to Onset of Obesity-Related Complications or Class 1 Obesity Aug 2029 Sep 2030 NCT07790861 Obesity / Overweight A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems (ATTAIN-CN) 3 192 Mean Percent Change from Baseline in Body Weight Mar 2028 Mar 2028 Not for promotional use 42 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Orforglipron (cont.)
Page 43
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05821959 Sensorineural Hearing Loss, Bilateral Gene Therapy Trial for Otoferlin Gene-Mediated Hearing Loss 3 48 AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery system) Oct 2028 Dec 2029 Not for promotional use 43 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – OTOF Gene Therapy
Page 44
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05023980 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) 3 282 To Evaluate Progression-Free Survival (PFS) of Pirtobrutinib (Arm A) Compared to Bendamustine and Rituximab (Arm B) Jul 2025 Oct 2027 NCT05254743 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314) 3 737 Percentage of Participants Achieving Complete Response (CR), Complete Remission With Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1 Oct 2027 Jan 2028 NCT04666038 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321) 3 238 Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC) Aug 2023 May 2027 NCT04965493 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322) 3 600 To Evaluate Progression-Free Survival (PFS) of Pirtobrutinib Plus Venetoclax and Rituximab (Arm A) Compared to Venetoclax and Rituximab (Arm B) Oct 2026 Oct 2027 Not for promotional use 44 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Pirtobrutinib
Page 45
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04662255 Mantle Cell Lymphoma Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) 3 500 To Compare Progression-Free Survival (PFS) of Pirtobrutinib as Monotherapy (Arm A) to Investigator Choice of Covalent BTK Inhibitor Monotherapy (Arm B) in Patients With Previously Treated Mantle Cell Lymphoma (MCL) Nov 2027 Jun 2030 NCT06721013 Immune Thrombocytopenia A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia 1/2 68 Ph. 1 - Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to Be Related to Study Drug Administration Feb 2028 Feb 2029 Not for promotional use 45 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Pirtobrutinib (cont.)
Page 46
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06653153 Alzheimer's Disease A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) 3 1400 Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rating Scale (CDR) Apr 2029 Oct 2030 Not for promotional use 46 Source: clinicaltrials.gov, October 20, 2026 Select Trials – Remternetug * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 47
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06662383 Obesity A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) 3 800 Percent Change from Baseline in Body Weight Nov 2026 Dec 2026 NCT06859268 Obesity A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6) 3 643 Percent Change from Baseline in Body Weight Apr 2028 Apr 2028 NCT07035093 Obesity / Chronic Low Back Pain A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7) 3 586 Percent Change from Baseline in Body Weight | Change from Baseline in Pain Intensity Per Numeric Rating Scale Sep 2027 Sep 2027 NCT07232719 Obesity / Overweight A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) 3 250 Percent Change from Baseline in Body Weight Jul 2027 Jul 2027 NCT07357415 Obesity / Overweight A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9) 3 600 Percent Change from Baseline in Body Weight Oct 2028 Nov 2028 NCT06383390 Atherosclerotic Cardiovascular Disease / CKD The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) 3 10000 Time to First Occurrence of Composite Endpoints Feb 2029 Feb 2029 NCT06260722 Type 2 Diabetes Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) 3 1250 Change from Baseline in HbA1c Aug 2026 Feb 2027 NCT06297603 Type 2 Diabetes Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) 3 320 Change from Baseline in HbA1c Oct 2026 Nov 2026 Not for promotional use 47 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Retatrutide
Page 48
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04194944 Non-Small Cell Lung Cancer A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) 3 261 Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) May 2023 Jun 2030 NCT04819100 Non-Small Cell Lung Cancer A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) 3 152 Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population Jan 2026 May 2028 NCT04211337 Medullary Thyroid Cancer A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) 3 291 Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) May 2023 Nov 2027 NCT03157128 Non-Small Cell Lung Cancer / Medullary Thyroid Cancer A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) 1/2 857 Phase 1: MTD, Incidence Rate and Category of Dose- Limiting Toxicities (DLTs) During the First 28-Day Cycle of LOXO-292 (Selpercatinib) Treatment Feb 2025 Feb 2027 NCT03899792 Solid Tumors / CNS Tumors (Pediatric) A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121) 1/2 36 Number of Participants With Dose-Limiting Toxicities (DLTs) Nov 2024 May 2029 Not for promotional use 48 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Selpercatinib
Page 49
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07213804 Ovarian Neoplasms A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (FRAmework-01) 3 1630 Progression-Free Survival (PFS), per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Nov 2028 Aug 2031 Not for promotional use 49 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Sofetabart Mipitecan
Page 50
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07174336 Breast Cancer A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (PIKALO- 2) 3 800 Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) (Part 1); Progression-Free Survival (PFS) (Part 2) May 2029 May 2033 NCT05768139 Breast Cancer First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) 1/2 880 Number of Participants Who Experience at Least 1 Dose-Limiting Toxicity (DLT) Jul 2030 Jul 2030 Not for promotional use 50 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Select Trials – Tersolisib
Page 51
2026 Q3 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05556512 Obesity / Overweight A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) 3 15374 Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE) or All-Cause Death Oct 2027 Oct 2027 NCT06914895 Type 1 Diabetes / Obesity A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) 3 905 Change from Baseline in HbA1c Nov 2026 Dec 2026 NCT06962280 Type 1 Diabetes / Obesity A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2) 3 465 Change from Baseline in HbA1c Nov 2026 Jul 2027 NCT06439277 Obesity (Adolescents) A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT- ADOLESCENTS-2) 3 300 Percent Change from Baseline in Body Mass Index (BMI) Oct 2027 Dec 2030 NCT06075667 Obesity / Overweight (Adolescents) A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities 3 160 Percent Change from Baseline in Body Mass Index (BMI) Jun 2026 Jul 2029 NCT07817875 Obesity (Pediatric) Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) 3 150 Percent Change from Baseline in Body Mass Index (BMI) Dec 2029 Dec 2032 NCT07165028 MASLD A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) 3 4500 Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes Aug 2030 Aug 2032 NCT06037252 Type 2 Diabetes / Obesity A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity 2 414 Percent Change from Baseline in Body Weight Jan 2026 Oct 2026 Not for promotional use 51 Source: clinicaltrials.gov, October 20, 2026 Select Trials – Tirzepatide * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 52
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Bimagrumab NCT06643728 Obesity / Overweight A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight 2 252 Percent Change from Baseline in Body Weight Jan 2026 Jan 2027 GS Insulin Receptor Agonist NCT07215312 Type 2 Diabetes A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin 2 100 Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) Nov 2026 Dec 2026 Macupatide NCT07215559 Obesity / Overweight / T2D A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes 2 200 Percent Change from Baseline in Body Weight Mar 2027 May 2027 Macupatide NCT07589608 Overweight / Obesity A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight 2 400 Percent Change from Baseline in Body Weight Sep 2027 Feb 2028 Not for promotional use 52 Source: clinicaltrials.gov, October 20, 2026 Early Phase Cardiometabolic Health * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 53
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Abdenoflast (VTX2735) NCT06836232 Recurrent Pericarditis An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis 2 50 Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Study Treatment Discontinuation (or Safety and Tolerability of VTX2735) Oct 2027 Oct 2027 Clazakizumab NCT07783802 Inflammatory Disorders A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event (CLARITY-CRP) 2 120 Percent Change from Baseline in hsCRP May 2027 Oct 2027 Nisotirostide NCT06897475 Type 2 Diabetes A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide 2 200 Change from Baseline in HbA1c May 2027 Jun 2027 Solbinsiran NCT07269210 Severe Hypertriglyceridemia A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia 2 60 Change from Baseline in Triglycerides Mar 2027 Aug 2027 Not for promotional use 53 Source: clinicaltrials.gov, October 20, 2026 Early Phase Cardiometabolic Health (cont.) * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 54
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Zotemtegrast NCT07415044 Ulcerative Colitis LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3) 2 1431 Percentage of Participants Who Achieve Clinical Remission With Modified Mayo Score (mMS) Jun 2030 Jul 2031 Zotemtegrast NCT06226883 Crohn's Disease A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease 2 385 Proportion of Participants With Endoscopic Response at Week 14 Determined Using the Simple Endoscopic Score-CD (SES-CD) Sep 2028 Jun 2030 XCL1/2 antibody NCT07533019 Non-Segmental Vitiligo A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo 2 66 Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75 May 2027 Sep 2027 XCL1/2 antibody NCT07533006 Alopecia Areata A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) 2 65 Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 Jun 2027 Oct 2027 Not for promotional use 54 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Early Phase Immunology
Page 55
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Amezosvatein NCT05304351 Herpes Zoster Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older 2 1516 Occurrence of Solicited Local and Systemic Signs and Symptoms Jun 2026 Mar 2032 Not for promotional use 55 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Early Phase Infectious Disease
Page 56
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Cleminorexton NCT07598708 Central Disorders of Hypersomnolence A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence 2/3 222 Change from Baseline in Mean Sleep Latency (Average of the First 4 Trials) on the Maintenance of Wakefulness Test (MWT) Sep 2027 Dec 2027 AT2R Antagonist NCT07285018 Diabetic Peripheral Neuropathic Pain A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain 2 150 Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) Jul 2027 Jul 2027 NAV 1.8 INH NCT07511816 Pain Following Third Molar Removal A Study of LY4515100 in Participants With Pain Following Third Molar Removal 2 212 Change from Baseline in Self-Reported Pain Intensity Nov 2026 Dec 2026 Anti-VEGF Gene Therapy NCT06517888 Vestibular Schwannoma Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma 1/2 27 AEs With Relationship to the Investigational Medicinal Product and/or to the Administration Procedure (including the Delivery Device) Aug 2029 Aug 2029 GBA1 Gene Therapy NCT04127578 Parkinson's Disease (GBA1 Mutation) Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) 1/2 32 Cumulative Number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Aug 2031 Aug 2031 Not for promotional use 56 Source: clinicaltrials.gov, October 20, 2026 Early Phase Neuroscience * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 57
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Buccal Film DMT NCT06524830 Treatment- Resistant Depression A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film Compared to Placebo in Patients With Treatment-Resistant Depression (ELUMINA) 2 142 Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score Dec 20261 Dec 20261 Not for promotional use 57 Source: clinicaltrials.gov, October 20, 2026 Early Phase Neuroscience (cont.) * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes 1 clinicaltrials.gov update in progress
Page 58
2026 Q3 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion GIPR Agonist LA NCT07169851 Chemotherapy- Induced Nausea / Vomiting A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer 2 204 Proportion of Participants With Complete Response (CR) in the Delayed Phase of CINV Dec 2026 Feb 2027 Not for promotional use 58 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, October 20, 2026 Early Phase Oncology
Page 59
2026 Q3 Earnings Not for promotional use 59 Trademarks All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent tradema rks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade na mes in this earnings update are referred to without the ® and symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their re sp ective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other comp ani es’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.